Biocartis confirms Idylla sales and patient value

September 11, 2015 News BioVox

The first half year results of Biocartis confirm a successful expansion of Idylla™, Biocartis’ fully automated molecular diagnostics system. 114 instruments (up to June 30, 2015) have been sold to various larger and smaller hospitals and distributors in and outside Europe. Idylla™ allows for faster and more accurate treatment for patients.

The recent research study of Dr. Filip Janku, MD from MD Anderson (Houston, United States) on the analytical sensitivity and specificity of the IdyllaTM BRAF Mutation Test, confirms that the IdyllaTM BRAF Mutation Test is rapid and has high concordance with other routinely used but more complex BRAF mutation–detecting tests.

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts